Nutritional Considerations in the Child With Liver Disease

Nutritional management of the infant and child with liver disease is highly dependent upon the type of liver disease. Acute liver disease, such as that secondary to viral hepatitis, requires no specific nutritional therapy with the exception that branched-chain amino acid supplements may be indicated in the management of hepatic encephalopathy. Nutritional management of the child with chronic liver disease depends upon whether or not cholestasis is present, since in that condition, large amounts of fat-soluble Vitamin supplements and medium-chain triglycerides are usually required for optimum growth. However, anicteric cirrhotic liver disease also presents nutritional challenges because of hypermetabolism, enteropathy, and increased protein oxidation. Certain inborn errors of metabolism that result in liver disease (including galactosemia, hepatorenal tyrosinemia, hereditary fructose intolerance, and Wilson's disease) have specific nutritional requirements. And, finally, the advent of pediatric liver transplantation has placed new emphasis on the importance of optimum nutritional management of the child with chronic liver disease, since improvement of nutritional status in the pretransplant period maximizes success of the transplant. This review will focus on the pathogenesis of malnutrition in childhood liver disease and will provide recommendations for nutritional assessment and monitoring as well as nutritional management of cholestatic liver disease, anicteric cirrhotic liver disease, and the inborn errors of metabolism enumerated above. Specific recommendations for nutritional management of the child awaiting liver transplantation will be provided. (C) Elsevier Science Inc. 1997.

Author: KB SCHWARZ, BRADY 320, 600 N WOLFE ST, BALTIMORE, MD 21287
Source: NUTRITION 1997 MAR;13(3):177-184

Anemia and Hepatitis C Treatment
In opposition to what seems logical, research demonstrates that becoming anemic while on Hepatitis C therapy is not such a bad thing.

Bristol-Myers Gains Momentum with All-Oral Hep C Therapy
In a recent study, over one third of previous non-responders cleared Hepatitis C with an interferon-free combo of two Bristol-Myers experimental drugs.

Hepatitis C Gains Access to Brain Cells
Helping to explain why Hepatitis C can cause extrahepatic manifestations (problems outside of the liver), American researchers confirmed that certain brain cells are susceptible to the Hepatitis C virus.